^
Association details:
| Biomarker: | ATM biallelic mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A091 - Targeting homologous recombination repair defects in lung cancer
Published date:
10/27/2019
Excerpt:
Amongst the PDX models containing a biallelic HRR mutation (ATM, BAP1, RAD51D & XRCC2), only ATM biallelic mutant models were sensitive to niraparib (2 out of 6).
